Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

Ocular Therapeutix Inc OCUL and Regeneron Pharmaceuticals Inc REGN have terminated the option and license agreement collaboration. The termination is effective immediately.
The collaboration with Regeneron was initially formed in 2016 to develop and commercialize products containing Ocular's sustained-release hydrogel technology in combination with Regeneron's large molecule vascular endothelial growth factor for eye diseases.
Under a 2020 amendment, the companies' efforts have focused on R&D of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space to treat retinal diseases.
Price Action: OCUL shares traded 3.04% lower at $10.51 and on the last check Friday.